Joyelle K Dominique1, Alberto A Ortiz-Osorno2, Joseph Fitzgibbon3, Devasena Gnanashanmugam4, Christopher Gilpin5, Timothy Tucker6, Sheila Peel7, Trevor Peter8, Peter Kim4, Steven Smith9. 1. Office of Global Research, Office of Science Management and Operations, Office of the Director. 2. Clinical Research Implementation Subject Matter Expert, Henry M. Jackson Foundation, Division of AIDS Therapeutic Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, Rockville, Maryland. 3. Therapeutic Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, Rockville, Maryland. 4. Adolescent and Pediatric Research Branch, Prevention Sciences Program, Division of AIDS. 5. World Health Organization, Geneva, Switzerland. 6. Strategic Evaluation, Advisory and Development Consulting, Cape Town, South Africa. 7. Diagnostics and Laboratory Monitoring, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland. 8. Diagnostics, Clinton Health Access Initiative, Gaborone, Botswana. 9. Office of Global Affairs, Office of the Secretary, US Department of Health and Human Services, Pretoria, South Africa.
Abstract
BACKGROUND: Novel diagnostics have been widely applied across human immunodeficiency virus (HIV) and tuberculosis prevention and treatment programs. To achieve the greatest impact, HIV and tuberculosis diagnostic programs must carefully plan and implement within the context of a specific healthcare system and the laboratory capacity. METHODS: A workshop was convened in Cape Town in September 2014. Participants included experts from laboratory and clinical practices, officials from ministries of health, and representatives from industry. RESULTS: The article summarizes best practices, challenges, and lessons learned from implementation experiences across sub-Saharan Africa for (1) building laboratory programs within the context of a healthcare system; (2) utilizing experience of clinicians and healthcare partners in planning and implementing the right diagnostic; and (3) evaluating the effects of new diagnostics on the healthcare system and on patient health outcomes. CONCLUSIONS: The successful implementation of HIV and tuberculosis diagnostics in resource-limited settings relies on careful consideration of each specific context. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Novel diagnostics have been widely applied across human immunodeficiency virus (HIV) and tuberculosis prevention and treatment programs. To achieve the greatest impact, HIV and tuberculosis diagnostic programs must carefully plan and implement within the context of a specific healthcare system and the laboratory capacity. METHODS: A workshop was convened in Cape Town in September 2014. Participants included experts from laboratory and clinical practices, officials from ministries of health, and representatives from industry. RESULTS: The article summarizes best practices, challenges, and lessons learned from implementation experiences across sub-Saharan Africa for (1) building laboratory programs within the context of a healthcare system; (2) utilizing experience of clinicians and healthcare partners in planning and implementing the right diagnostic; and (3) evaluating the effects of new diagnostics on the healthcare system and on patient health outcomes. CONCLUSIONS: The successful implementation of HIV and tuberculosis diagnostics in resource-limited settings relies on careful consideration of each specific context. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Shabir Banoo; David Bell; Patrick Bossuyt; Alan Herring; David Mabey; Freddie Poole; Peter G Smith; N Sriram; Chansuda Wongsrichanalai; Ralf Linke; Rick O'Brien; Mark Perkins; Jane Cunningham; Precious Matsoso; Carl Michael Nathanson; Piero Olliaro; Rosanna W Peeling; Andy Ramsay Journal: Nat Rev Microbiol Date: 2010-12 Impact factor: 60.633
Authors: Bruce A Larson; Alana Brennan; Lynne McNamara; Lawrence Long; Sydney Rosen; Ian Sanne; Matthew P Fox Journal: Bull World Health Organ Date: 2010-04-16 Impact factor: 9.408
Authors: Kate Clouse; Liesl Page-Shipp; Heather Dansey; Bridgette Moatlhodi; Lesley Scott; Jean Bassett; Wendy Stevens; Ian Sanne; Annelies Van Rie Journal: S Afr Med J Date: 2012-09-07
Authors: Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla Journal: Lancet Infect Dis Date: 2013-03-24 Impact factor: 25.071
Authors: Janne Estill; Matthias Egger; Nello Blaser; Luisa Salazar Vizcaya; Daniela Garone; Robin Wood; Jennifer Campbell; Timothy B Hallett; Olivia Keiser Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: Mark J Siedner; Jessica E Haberer; Mwebesa Bosco Bwana; Norma C Ware; David R Bangsberg Journal: BMC Med Inform Decis Mak Date: 2012-06-21 Impact factor: 2.796
Authors: Bruce A Larson; Kathryn Schnippel; Alana Brennan; Lawrence Long; Thembi Xulu; Thapelo Maotoe; Sydney Rosen; Ian Sanne; Matthew P Fox Journal: AIDS Res Treat Date: 2013-07-16
Authors: Mai T Pho; Sarang Deo; Kara M Palamountain; Moses Lutaakome Joloba; Francis Bajunirwe; Achilles Katamba Journal: PLoS One Date: 2015-04-01 Impact factor: 3.240